Boehringer Ingelheim International Gmbh

Pfizer Corporation

Hydra Biosciences, Inc.

Michael Dennis Lowe

Christopher Ronald Sarko

Christoph Martin Dehnhardt

Joseph Walter Strohbach

Eddine Saiah

Akshay Patny

David Hepworth

Kevin Joseph Curran

Xiaolun Wang

Christoph Wolfgang Zapf

Nikolaos Papaioannou

Arthur Lee

Frank Eldridge Lovering

Katherine Lin Lee

Stephen Wayne Wright

John David Trzupek

Joel A Goldberg

Richard Vargas

Seungil Han

Lori Krim Gavrin

David R Anderson

Mark Edward Bunnage

Horng-Chih Huang

John Paul Mathias

Betsy Susan Pierce

Michael Robert Turner

Thierry Bouyssou

Xinyuan Edward Wu

Lana Louise Smith Keenan

Simon Surprenant

Niklas Heine

Hidenori Takahashi

Hossein Razavi

Dirk Gottschling

Zhonghua Zhang

John David Ginn

Jehrod Burnett Brenneman

Edward S Tasber

Maolin Yu

Steven Richard Brunette

John A Westbrook

Jianwen Cui

Tamara Denise Hopkins

Paul Nicklin

David Randolph Anderson

Joel Adam Goldberg

Steven Brunette

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Bicyclic-fused heteroaryl or aryl compounds

The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Inhibitors of TRPC6

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein Rto R, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Alkoxy pyrazoles as soluble guanylate cyclase activators

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Growing community of inventors

White Plains, NY, United States of America

Michael Dennis Lowe